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RESULTS:
 
 From the best imag-
inable state, each 20-point decrement in respondent’s
self-rated health status yielded significantly greater incon-
sistency in their valuation of EQ-5D health states con-
trolling for age and sex. Inclusion of education and in-
come reduced this effect slightly, yet it remained statistically
significant. CONCLUSIONS: Respondents in poor health
demonstrate greater difficult in valuing health states in a
logically consistent manner. Censoring survey data to re-
move inconsistent respondents may violate the principle
of using representative population values in evaluating
cost-effectiveness of health care.
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Increasingly over the past several years, quality of life and
patient-reported outcomes data have been submitted as
part of NDA and sNDA packages to US and Interna-
tional regulatory agencies. These data provide important
information to prescribing clinicians and patients regard-
ing therapeutic and humanistic benefits of drug therapy.
OBJECTIVES: To evaluate the marketed drugs with the
terminology ‘quality-of-life’ in the product labeling.
METHODS: A search of the Physician Desk Reference
database was conducted to identify those products that
included the term “quality-of-life” (QoL) within the Phy-
sician Package Insert. The Summary Basis of Approval
(SBA) of each product was reviewed to evaluate the re-
search processes followed, use of psychometrically vali-
dated instruments, and the final resulting language at-
tained within the labeling with respect to QoL. RESULTS:
Twenty-two products referencing the term “quality-of-
life” in the product labeling were identified. FDA ap-
proval of these products occurred mainly in the years
from 1982 to 2000 with increasing frequency of QoL in-
clusion in recent years. Upon SBA review we found the
majority of the products (13/22) utilized a validated in-
strument during clinical investigations. Only one of the
22 SBAs specifically described and discussed the issue of
instrument validation. In the early years approved label-
ing claims included more broad, sweeping terminology
when describing QoL results. In more recent, cases, ap-
proved QoL labeling claims were more narrowly defined
and more rigorously worded with respect to trial results
and specific patient-reported instruments. CONCLUSION:
Over the course of the time, the approach has become
more rigorous resulting in a more refined QoL research
process. These findings have demonstrated that the use of
QoL descriptive data has increased, particularly a greater
degree of comprehensive information pertaining to QoL
instruments, research, and data can be found in the SBAs.
Hence, more relevant and specific QoL information is
claimed in the Physician Package Insert.
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OBJECTIVES:
 
 The use of health-related quality of life
(HRQL) claims in drug promotions is under active dis-
cussion by the pharmaceutical industry, the FDA, and
other stakeholders. However, the extent to which phar-
maceutical companies have previously promoted HRQL
messages in advertisements in medical journals, and
the nature of those messages, has not been quantified.
METHODS: We performed a content analysis of all
pharmaceutical advertisements appearing in three general
medical journals (AIM, JAMA, and NEJM), and three
specialty journals (Circulation, Gastroenterology, and
Neurology) in January, July, and October annually from
1990–1999. Two reviewers analyzed each advertisement
for the presence and type of HRQL content, and for sup-
porting evidence. We distinguished explicit HRQL
claims, which used words, such as “quality of life or “pa-
tient satisfaction,” from implicit claims, which we de-
fined broadly as pictures implying improved physical,
emotional/mental, or social functioning. RESULTS: We
judged that HRQL messages appeared in 520 (24.3%) of
2142 advertisements examined. Advertisements with
HRQL content increased from 1990–94 to 1995–99
(19.9% vs. 29.6%, p  0.0001). 56% of HRQL con-
tained implicit messages only, followed by ads that used
both implicit and explicit messages (35%), and ads con-
taining explicit messages alone (9%). Overall, few ads
(12%) contained any clear supporting evidence. Mes-
sages that implied or stated improved overall well-being
or mental health were most common (78% of all HRQL
ads), followed by enhanced physical or social functioning
(63% and 25%, respectively) (numbers add to 100%,
because a single ad could contain multiple messages).
CONCLUSIONS: Advertisements conveying HRQL mes-
sages are used frequently by drug manufacturers in medi-
cal journals, and are increasing over time. In the future,
researchers should better define HRQL, and probe more
deeply into what comprises substantiating evidence, per-
haps by incorporating the concept of “patient-reported
outcomes.”
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